High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Oncol
Egile Nagusiak: Silk, Ann W., Kaufman, Howard L., Curti, Brendan, Mehnert, Janice M., Margolin, Kim, McDermott, David, Clark, Joseph, Newman, Jenna, Bommareddy, Praveen K., Denzin, Lisa, Najmi, Saltanat, Haider, Azra, Shih, Weichung, Kane, Michael P., Zloza, Andrew
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6965158/
https://ncbi.nlm.nih.gov/pubmed/31998643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01483
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak